KLOW Blend: Multi-Peptide Regenerative Stack

KLOW is a research blend whose name is an acronym of its four components: KPV, BPC-157 (the “L” for its frequent listing as the lipid-stable variant), GHK-Cu (the “O” for the copper-bound tripeptide often written as GHK-Cu, sometimes notated with an “O” for the carbonyl/copper coordination), and TB-500 (Thymosin beta-4 fragment, the “W” reflecting its wound-healing profile). Each component targets a distinct but complementary biological pathway, which is why the blend is widely studied as a single regenerative composition.

Components and Typical Research Ratios

Most published research formulations describe an 80 mg vial with the following approximate distribution. Exact ratios vary between research suppliers.

• GHK-Cu — ~50 mg. Glycyl-L-histidyl-L-lysine bound to copper(II). A naturally occurring tripeptide-copper complex involved in wound healing, collagen and elastin synthesis, and modulation of more than 4,000 human genes (Pickart & Margolina, 2018).
• KPV — ~10 mg. The C-terminal tripeptide (Lys-Pro-Val) of α-MSH. Studied for NF-κB pathway inhibition, mast-cell stabilization, and reduction of pro-inflammatory cytokines in colitis and dermatologic models (Brzoska et al., 2008).
• BPC-157 — ~10 mg. A 15-amino-acid synthetic pentadecapeptide derived from a sequence in human gastric juice. Investigated for tendon, ligament, muscle, and gastrointestinal repair, with upregulation of VEGFR2 and nitric-oxide pathways (Sikiric et al., 2018).
• TB-500 — ~10 mg. A synthetic fragment of Thymosin β4 that promotes actin polymerization, cell migration, angiogenesis, and modulation of inflammatory cytokines in injury models (Goldstein et al., 2012).

Mechanistic Rationale for Combination

The four components of KLOW act on parallel rather than redundant pathways, which is the rationale researchers cite for studying them together:

• Matrix and collagen synthesis (GHK-Cu): Stimulates dermal fibroblasts and upregulates genes involved in collagen, glycosaminoglycan, and decorin production while supporting copper-dependent enzymes such as lysyl oxidase.
• Anti-inflammatory signaling (KPV): Crosses cellular membranes via the PepT1 transporter and inhibits NF-κB translocation, reducing TNF-α and IL-1β production. Preclinical colitis studies have shown reduced disease activity index and mucosal healing.
• Angiogenesis and cytoprotection (BPC-157): Modulates VEGFR2/eNOS signaling, promotes capillary network formation, and demonstrates organoprotective effects across the GI tract, tendons, and CNS in rat models.
• Cell migration and remodeling (TB-500): Binds G-actin to enable cytoskeletal reorganization, supporting keratinocyte and endothelial cell migration into wound beds and accelerating epithelial closure in preclinical assays.

Preclinical Research Findings

• Soft-tissue and tendon repair: BPC-157 and TB-500 have independently demonstrated accelerated Achilles tendon and medial collateral ligament healing in rat models, with improved tensile strength and organized collagen deposition (Chang et al., 2011; Philp et al., 2006).
• Cutaneous wound healing: GHK-Cu has decades of dermatologic literature documenting accelerated re-epithelialization, reduced scarring, and improved tensile strength of healed skin (Pickart et al., 2015).
• Gastrointestinal inflammation: KPV has reduced histologic scores and pro-inflammatory cytokines in DSS- and TNBS-induced colitis models, and BPC-157 has shown protection in NSAID-induced gastric lesion models (Dalmasso et al., 2008; Sikiric et al., 2018).
• Cardiac and skeletal muscle: TB-500 has been studied in post-infarct cardiac remodeling, where it promotes epicardial progenitor migration and reduces fibrosis in murine models (Smart et al., 2007).

Pharmacokinetic Considerations

The four peptides differ significantly in size, charge, and stability, which is why they are reconstituted together but act on different timescales:

• GHK-Cu (340 Da): Small tripeptide-copper complex with rapid tissue uptake and a plasma half-life of minutes; activity is sustained through copper deposition in target tissues.
• KPV (358 Da): Tripeptide actively transported into epithelial cells; plasma half-life is short but intracellular activity persists.
• BPC-157 (1419 Da): Pentadecapeptide that is stable in human gastric juice and shows a plasma half-life of roughly 4 hours after subcutaneous administration in research models.
• TB-500 (4963 Da): Larger peptide fragment with a longer effective duration of action (days) in tissue, supported by its slow clearance and high tissue affinity.

Reconstitution and Handling

KLOW vials are typically reconstituted with bacteriostatic water. Because GHK-Cu is light- and oxidation-sensitive, reconstituted blends should be stored refrigerated (2–8 °C), protected from light, and used within the timeframe established for the least-stable component (commonly cited as 30 days). See the BioPrime Reconstitution & Storage Guide for general best practices.

Research Status

None of the individual KLOW components are FDA-approved drugs. They are investigational compounds studied in preclinical and limited clinical research settings. BioPrime offers KLOW strictly as a reference blend for in-vitro and preclinical laboratory research by qualified professionals.

References

• Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987.
• Brzoska T, et al. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects. Endocr Rev. 2008;29(5):581–602.
• Sikiric P, et al. Stable gastric pentadecapeptide BPC 157, robust to many therapy effects. Curr Pharm Des. 2018;24(18):1990–2001.
• Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37–51.
• Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178.
• Chang CH, et al. The promotion of chondrogenesis, osteogenesis, and reduction of collagenase activity by thymosin β-4. J Biomed Mater Res A. 2011.
• Smart N, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182.
• Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108.